GGrantIndex
← Leaderboards

Brigitte N Gomperts

University Of California Los Angeles

$6,323,802
Attributed
$9,536,754
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,536,754 · 6

By mechanism

R01$4,919,270 · 3
U01$3,984,334 · 2
K08$633,150 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungCellsLung DiseasesBiologyTissuesPreventAirway EpitheliumEpithelial CellsPhenotypeChronicEpithelialPathogenesisEpitheliumSmall MoleculeNovel TherapeuticsSignal TransductionInjuryStem CellsExtracellular MatrixFibroblastsBiological ModelsMesenchymalProgramsInduced Pluripotent Stem Cell

Grant awards (25)

Cell-cell and cell-matrix interactions driving progressive fibrosis in interstitial lung diseases$794,976
U01 · FY2025 · HL · contact PI
Cell-cell and cell-matrix interactions driving progressive fibrosis in interstitial lung diseases$822,275
U01 · FY2024 · HL · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$617,814
U01 · FY2024 · HL · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$630,424
U01 · FY2023 · HL · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$630,424
U01 · FY2022 · HL · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$488,421
U01 · FY2021 · HL · contact PI
Developing a targeted chemoprevention strategy for Non-Small Cell Lung Cancer$352,275
R01 · FY2020 · CA · contact PI
Determining the role of SARS-CoV-2 in driving premalignancy of the airway$156,000
R01 · FY2020 · CA · contact PI
Developing a targeted chemoprevention strategy for Non-Small Cell Lung Cancer$341,706
R01 · FY2019 · CA · contact PI
Developing a targeted chemoprevention strategy for Non-Small Cell Lung Cancer$352,275
R01 · FY2018 · CA · contact PI
Development of a High-Throughput Screen for Pre-therapeutic Discovery in Idiopathic Pulmonary Fibrosis$374,274
R01 · FY2017 · GM · contact PI
Developing a targeted chemoprevention strategy for Non-Small Cell Lung Cancer$352,275
R01 · FY2017 · CA · contact PI
Development of a High-Throughput Screen for Pre-therapeutic Discovery in Idiopathic Pulmonary Fibrosis$405,875
R01 · FY2016 · GM · contact PI
Developing a targeted chemoprevention strategy for Non-Small Cell Lung Cancer$352,275
R01 · FY2016 · CA · contact PI
Development of a High-Throughput Screen for Pre-therapeutic Discovery in Idiopathic Pulmonary Fibrosis$333,310
R01 · FY2015 · GM · contact PI
Progenitor Cells in Airway Repair$362,855
R01 · FY2013 · HL · contact PI
Progenitor Cells in Airway Repair$381,150
R01 · FY2012 · HL · contact PI
Progenitor Cells in Airway Repair$385,000
R01 · FY2011 · HL · contact PI
Progenitor Cells in Airway Repair$385,000
R01 · FY2010 · HL · contact PI
Progenitor Cells in Airway Repair$385,000
R01 · FY2009 · HL · contact PI
Cytokine Regulation of the Pulmonary Epithelium$126,630
K08 · FY2009 · HL · contact PI
Cytokine Regulation of the Pulmonary Epithelium$126,630
K08 · FY2008 · HL · contact PI
Cytokine Regulation of the Pulmonary Epithelium$126,630
K08 · FY2007 · HL · contact PI
Cytokine Regulation of the Pulmonary Epithelium$126,630
K08 · FY2006 · HL · contact PI
Cytokine Regulation of the Pulmonary Epithelium$126,630
K08 · FY2005 · HL